Loading...
Docoh

Abbvie (ABBV)

Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
29 Sep 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Filed: 27 May 22
Utility
Bispecific Binding Molecules
29 Sep 22
The present disclosure provides novel bispecific molecules that binds to human Survivin and human CD3, and methods of making and using the same.
Adam S. Chervin, Feng Dong, Edward B. Reilly, Jennifer D. Stone, Michael K. White
Filed: 1 Nov 21
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
22 Sep 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Ahmed A. Othman, Mohamed-Eslam F. Mohamed, Ben Klünder, Aileen L. Pangan
Filed: 27 May 22
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
22 Sep 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Filed: 27 May 22
Utility
Methods for Treating HCV
15 Sep 22
The present invention features interferon-free therapies for the treatment of HCV.
Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang, Sven Mensing
Filed: 24 Sep 21
Utility
Anti-egfr Antibodies and Antibody Drug Conjugates
15 Sep 22
The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Edward B. REILLY, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
Filed: 20 Oct 21
Utility
ANTI-CD40 Antibodies and Uses Thereof
15 Sep 22
The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof.
Lorenzo Benatuil, Maria A. Argiriadi, Bradford L. Mcrae, Chung-Ming Hsieh, David A. Egan, John E. Harlan, Russell A. Judge, Rui Wang, Gillian A. Kingsbury
Filed: 7 Oct 21
Utility
Methods of Treatment of Diseases In Which IL-13 Activity Is Detrimental Using ANTI-IL-13 Antibodies
8 Sep 22
The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
Filed: 10 May 22
Utility
Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
8 Sep 22
The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Didier Philippe Robert Schils, Sam Bob Corveleyn, Herman Augustinus De Kock, Matthew Beau Dufek
Filed: 27 May 22
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
8 Sep 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2.3-]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.
Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson, In-Ho Song, Jose Jeffrey V. Enejosa
Filed: 9 Feb 22
Utility
Methods of Treating Crohn's Disease and Ulcerative Colitis
1 Sep 22
The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor.
Aileen L. Pangan, Roopal B. Thakkar, Steven Jungerwirth, Ana Paula Machado De Lacerda, Anne M. Robinson, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Filed: 28 Apr 22
Utility
Spiro-cyclic amine derivatives as S1P modulators
30 Aug 22
Axel Stoit, Wouter I. Iwema Bakker, Hein K. A. C. Coolen, Maria J. P. van Dongen, Nicolas J.-L. D. Leflemme, Adrian Hobson
Filed: 31 Aug 20
Utility
Anti-BCMA heavy chain-only antibodies
30 Aug 22
Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
Nathan Trinklein, Shelley Force Aldred, Starlynn Clarke, Wim van Schooten
Filed: 20 Jun 18
Utility
Combination Therapy of a Type II ANTI-CD20 Antibody with a Selective BCL-2 Inhibitor
25 Aug 22
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Filed: 30 Mar 22
Utility
ANTI-CD40 Antibody Drug Conjugates
25 Aug 22
Adrian D. Hobson, Jason Z. Oh, Michael J. McPherson, Wendy Waegell, Shaughn H. Bryant, Axel Hernandez, Jr., Claire L. Ihle, Christopher C. Marvin, Olivia A. Perng, Ling C. Santora, Lu Wang, Lu Wang
Filed: 29 Nov 18
Utility
Medication Packaging and Dispensing System
25 Aug 22
A medication packaging and dispensing system is provided.
Lori Kim, Alexandra Breban-Lopez, Bhimaprasad Medhal, Dejan Bojicic, Guy Upchurch, John G. Finch, Lewis Sita
Filed: 10 May 22
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
25 Aug 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process.
Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
Filed: 2 May 22
Utility
CD3 binding antibodies
23 Aug 22
The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
Filed: 1 Oct 21
Utility
Methods of Administering Elagolix
18 Aug 22
The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis.
Mohamad Shebley, Ling Cheng, Pooja Manchandani
Filed: 28 Jan 22
Utility
Macrocyclic MCL-1 Inhibitors and Methods of Use
18 Aug 22
Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Yujia Dai, Jane Gong, Roberto Risi, Yiyun Yu, Guidong Zhu
Filed: 22 Apr 22
Patents are sorted by USPTO publication date, most recent first